MCID: THY125
MIFTS: 49

Thyroid Gland Medullary Carcinoma

Categories: Cancer diseases, Endocrine diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Thyroid Gland Medullary Carcinoma

MalaCards integrated aliases for Thyroid Gland Medullary Carcinoma:

Name: Thyroid Gland Medullary Carcinoma 11 14
Medullary Thyroid Carcinoma 11 14
Medullary Carcinoma of the Thyroid Gland 11
Ultimobranchial Thyroid Tumour 11
Ultimobranchial Thyroid Tumor 11
Thyroid Cancer, Medullary 43

Classifications:



External Ids:

Disease Ontology 11 DOID:3973
MeSH 43 C536914
NCIt 49 C3879
SNOMED-CT 68 255032005
UMLS 71 C0238462

Summaries for Thyroid Gland Medullary Carcinoma

Disease Ontology: 11 A thyroid gland carcinoma that has material basis in parafollicular cells.

MalaCards based summary: Thyroid Gland Medullary Carcinoma, also known as medullary thyroid carcinoma, is related to multiple endocrine neoplasia, type iia and thyroid cancer, nonmedullary, 1. An important gene associated with Thyroid Gland Medullary Carcinoma is RET (Ret Proto-Oncogene), and among its related pathways/superpathways are Gastrin signaling pathway and miRNAs involvement in the immune response in sepsis. The drugs Radiopharmaceuticals and 3-Iodobenzylguanidine have been mentioned in the context of this disorder. Affiliated tissues include thyroid, lymph node and myeloid, and related phenotype is no phenotypic analysis.

Related Diseases for Thyroid Gland Medullary Carcinoma

Diseases related to Thyroid Gland Medullary Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 512)
# Related Disease Score Top Affiliating Genes
1 multiple endocrine neoplasia, type iia 33.2 RET NTRK1 MEN1 CALCA
2 thyroid cancer, nonmedullary, 1 32.8 MIR222 MIR221 MIR146B MIR138-1
3 multiple endocrine neoplasia, type iib 32.7 RET NTRK1 MIR222 MEN1 CEACAM5 CALCA
4 multiple endocrine neoplasia 32.5 TG SST RET MEN1 GAST CHGA
5 pheochromocytoma 31.7 SST RET NTRK1 MEN1 CHGA CALCA
6 thyroid carcinoma, familial medullary 31.6 TG SST RET NTRK1 MEN1 GAST
7 hyperparathyroidism 31.6 RET MEN1 GAST CHGA CALCA
8 thyroiditis 31.5 TG RET CALCA
9 goiter 31.5 TG SST RET PAX8 CALCA
10 hypothyroidism 31.4 TG SST RET PAX8 CALCA
11 conn's syndrome 31.3 SST RET MEN1 CHGA CALCA
12 nodular goiter 31.3 TPCN1 TG RET CALCA
13 adenoma 31.3 TG SST RET MEN1 CHGA
14 hashimoto thyroiditis 31.3 TG RET MIR146B CALCA
15 differentiated thyroid carcinoma 31.2 RET PAX8 NTRK1
16 thyroid cancer, nonmedullary, 2 31.2 TG PAX8 CALCA
17 neuroendocrine tumor 31.2 SST RET PAX8 MEN1 GAST CHGA
18 primary hyperparathyroidism 31.2 RET MEN1 GAST CHGA CALCA
19 carcinoid syndrome 31.1 SST CHGA CALCA
20 carcinoid tumors, intestinal 31.1 SST MEN1 GAST CHGA
21 papillary carcinoma 31.0 TG RET PAX8 NTRK1 CHGA CALCA
22 multiple endocrine neoplasia, type i 31.0 SST RET MEN1 GAST CHGA
23 parathyroid adenoma 30.9 TG RET MEN1 GAST CHGA CALCA
24 parathyroid carcinoma 30.9 RET MEN1 CALCA
25 parathyroid gland disease 30.9 TG RET MEN1 GAST CALCA
26 paraganglioma 30.8 TG SST RET NTRK1 MEN1 CHGA
27 multiple mucosal neuroma 30.8 RET MEN1 CALCA
28 malignant pheochromocytoma 30.8 SST RET CHGA
29 multinodular goiter 30.8 TG RET PAX8 MIR222 MIR183 MIR146B
30 hyperthyroidism 30.8 TG SST CALCA
31 neuroendocrine carcinoma 30.8 SST MEN1 GAST CHGA CALCA
32 carney complex variant 30.7 SST RET MEN1
33 extra-adrenal pheochromocytoma 30.7 RET CHGA
34 pituitary adenoma 30.7 SST RET MIR149 MEN1 CHGA
35 small cell cancer of the lung 30.7 SST GAST CHGA CEACAM5 CALCA
36 ectopic cushing syndrome 30.7 SST CHGA CALCA
37 neurofibromatosis, type i 30.7 SST RET MEN1
38 endemic goiter 30.7 TG PAX8 CALCA
39 lymphatic system disease 30.6 MIR9-1 MIR222 MIR221 MIR149 MIR146B
40 endocrine gland cancer 30.6 SST RET MIR9-1 MIR222 MIR221 MIR183
41 insulinoma 30.6 SST MEN1 GAST CHGA CALCA
42 papillary thyroid microcarcinoma 30.6 TG CALCA
43 fetal adenoma 30.5 TG CALCA
44 hemangioma 30.5 RET MEN1 CHGA CALCA
45 bone disease 30.5 MIR9-1 MIR222 MIR221 CALCA
46 thyroid lymphoma 30.5 TG RET CALCA
47 follicular adenoma 30.5 TG RET PAX8 NTRK1 MIR222 MIR221
48 thyroid gland follicular carcinoma 30.4 TPCN1 TG RET PAX8 NTRK1 MIR222
49 pituitary gland disease 30.4 SST MIR9-1 MEN1
50 horner's syndrome 30.4 TG CALCA

Graphical network of the top 20 diseases related to Thyroid Gland Medullary Carcinoma:



Diseases related to Thyroid Gland Medullary Carcinoma

Symptoms & Phenotypes for Thyroid Gland Medullary Carcinoma

MGI Mouse Phenotypes related to Thyroid Gland Medullary Carcinoma:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 no phenotypic analysis MP:0003012 9.23 CHGA MIR138-1 MIR9-1 NTRK1 PAX8 RET

Drugs & Therapeutics for Thyroid Gland Medullary Carcinoma

Drugs for Thyroid Gland Medullary Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 88)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Radiopharmaceuticals Phase 3
2 3-Iodobenzylguanidine Phase 3
3
Everolimus Approved Phase 2 159351-69-6 70789204 6442177
4
Vorinostat Approved, Investigational Phase 2 149647-78-9 5311
5
Histamine Approved, Investigational Phase 1, Phase 2 51-45-6 774
6
Sunitinib Approved, Investigational Phase 2 557795-19-4 5329102
7
Capecitabine Approved, Investigational Phase 1, Phase 2 154361-50-9 60953
8
Lenvatinib Approved, Investigational Phase 2 417716-92-8 9823820
9
Salmon calcitonin Approved, Investigational Phase 2 47931-85-1 155817456
10
Dacarbazine Approved, Investigational Phase 1, Phase 2 4342-03-4 2942 5351166
11
Bortezomib Approved, Investigational Phase 1, Phase 2 179324-69-7 387447 93860
12
Glycine Approved, Nutraceutical, Vet_approved Phase 1, Phase 2 56-40-6 750
13
D-Tyrosine Approved, Experimental, Investigational, Nutraceutical Phase 2 133585-56-5, 60-18-4, 556-02-5 1153 6057
14
Calcitonin gene-related peptide Investigational Phase 2 83652-28-2 91976570
15 Immunosuppressive Agents Phase 2
16 Immunoglobulins Phase 2
17 Antibodies Phase 2
18 Immunologic Factors Phase 2
19 Histone Deacetylase Inhibitors Phase 2
20 Antibodies, Bispecific Phase 2
21 Neurotransmitter Agents Phase 1, Phase 2
22
Histamine phosphate Phase 1, Phase 2 51-74-1 134614
23 Angiogenesis Inhibitors Phase 2
24 Alkylating Agents Phase 1, Phase 2
25 Antineoplastic Agents, Alkylating Phase 1, Phase 2
26 Antimetabolites Phase 1, Phase 2
27
Calcitonin Phase 2
28 Katacalcin Phase 2 16172926
29
Imatinib Mesylate Phase 1, Phase 2 220127-57-1
30 Proteasome Inhibitors Phase 1, Phase 2
31
Sirolimus Approved, Investigational Phase 1 53123-88-9 5284616 6436030
32
Metronidazole Approved Phase 1 443-48-1, 69198-10-3 4173
33
Sargramostim Approved, Investigational Phase 1 123774-72-1
34
Carboplatin Approved Phase 1 41575-94-4 10339178 38904
35
Paclitaxel Approved, Vet_approved Phase 1 33069-62-4 36314
36
Trastuzumab Approved, Investigational Phase 1 180288-69-1
37
Octreotide Approved, Investigational Phase 1 83150-76-9 383414 6400441
38
Vinorelbine Approved, Investigational Phase 1 71486-22-1 44424639 60780
39
Miconazole Approved, Investigational, Vet_approved Phase 1 22916-47-8 4189
40
Clotrimazole Approved, Vet_approved Phase 1 23593-75-1 2812
41
Mechlorethamine Approved, Investigational Phase 1 51-75-2 4033
42
Nivolumab Approved Phase 1 946414-94-4
43
Cholecystokinin Approved, Investigational Phase 1 9011-97-6 16129670
44
D-Phenylalanine Approved, Experimental, Investigational, Nutraceutical Phase 1 63-91-2, 673-06-3 6140 71567
45
Vatalanib Investigational Phase 1 212141-54-3 151194
46
Molgramostim Investigational Phase 1 99283-10-0
47
Polygeline Experimental Phase 1 66455-30-9
48 Antibodies, Monoclonal Phase 1
49 Anti-Bacterial Agents Phase 1
50 Vaccines Phase 1

Interventional clinical trials:

(show top 50) (show all 55)
# Name Status NCT ID Phase Drugs
1 An International, Randomised, Double-Blind, Two-Arm Study To Evaluate The Safety And Efficacy Of Vandetanib 150 And 300mg/Day In Patients With Unresectable Locally Advanced Or Metastatic Medullary Thyroid Carcinoma With Progressive Or Symptomatic Disease Active, not recruiting NCT01496313 Phase 4 300mg vandetanib;150mg vandetanib
2 123I-MIBG Scintigraphy in Patients Being Evaluated for Neuroendocrine Tumors Unknown status NCT01373736 Phase 3 123I-meta-iodobenzylguanidine
3 A Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Trial to Compare the Efficacy and Safety of Anlotinib Versus Placebo in Patients With Medullary Thyroid Carcinoma(ALTER01031) Completed NCT02586350 Phase 2, Phase 3 Anlotinib;Placebo
4 A Phase II Study to Investigate the Efficacy of RAD001 (Afinitor®, Everolimus) in Patients With Irresectable Recurrent or Metastatic Differentiated, Undifferentiated (Anaplastic) and Medullary Thyroid Carcinoma Unknown status NCT01118065 Phase 2 everolimus
5 A Phase II Study of GW 786034 (Pazopanib) in Advanced Thyroid Cancer Completed NCT00625846 Phase 2 Pazopanib Hydrochloride
6 Phase II Study of Sunitinib in Iodine Refractory Differentiated Thyroid Cancer and Metastatic Medullary Carcinoma of Thyroid With Functional Imaging Correlation Completed NCT00519896 Phase 2 sunitinib malate
7 Phase II Study of Histone Deacetylase Inhibitor SAHA (Vorinostat) in Patients With Metastatic Thyroid Carcinoma Completed NCT00134043 Phase 2 vorinostat
8 A Phase II Trial of 17-Allylaminogeldanamycin (17AAG) in Advanced Medullary and Differentiated Thyroid Carcinoma Completed NCT00118248 Phase 2 tanespimycin
9 A Multi-center, Single-arm, Open-label Phase II Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Sorafenib in Japanese Patients With Anaplastic Thyroid Carcinoma or Locally Advanced or Metastatic Medullary Thyroid Carcinoma Completed NCT02114658 Phase 2 Sorafenib (Nexavar,BAY43-9006)
10 Phase 2 Study of Anlotinib in Advanced Medullary Thyroid Carcinoma Completed NCT01874873 Phase 2 Anlotinib
11 A Multi-center , Opened, Phase II Study of Safety and Efficacy of Sulfatinib in Advanced Medullary Thyroid Carcinoma ( MTC) and Iodine-refractory Differentiated Thyroid Carcinoma (DTC) Completed NCT02614495 Phase 2 Surufatinib
12 Phase I/II Trial of Vandetanib (ZD6474, ZACTIMA) in Children and Adolescents With Hereditary Medullary Thyroid Carcinoma Completed NCT00514046 Phase 1, Phase 2 Vandetanib
13 Phase II Two-step Radioimmunotherapy Clinical Study in Medullary Thyroid Carcinoma Completed NCT00467506 Phase 2 bispecific antibody and di-DTPA-131I
14 Sorafenib as Adjuvant to Radioiodine Therapy in Non-Medullary Thyroid Carcinoma Completed NCT00887107 Phase 2 Sorafenib (nexavar)
15 An Open Label, Two Stage, Phase II Study to Evaluate the Efficacy and Tolerability of ZD6474 in Patients With Locally Advanced or Metastatic Hereditary Medullary Thyroid Carcinoma. Completed NCT00098345 Phase 2 ZD6474 (vandetanib)
16 A Phase I/II, Open-label Study to Evaluate the Safety and Tolerability of Vandetanib 300 mg/Day in Japanese Patients With Unresectable Locally Advanced or Metastatic Medullary Thyroid Carcinoma Completed NCT01661179 Phase 1, Phase 2 Vandetanib 300mg
17 Pharmacokinetic and Imaging Optimization Study of Pretargeted Immuno-PET Using the Anti-CEA x Anti-HSG TF2 Bispecific Antibody and 68Ga-IMP-288 Peptide in Patients With Recurrences of Medullary Thyroid Carcinoma. Completed NCT01730638 Phase 1, Phase 2 • TF2 and 68 Ga-IMP-288
18 Neoadjuvant Treatment With Selpercatinib in RET-Altered Thyroid Cancers Recruiting NCT04759911 Phase 2 Selpercatinib
19 A Single-arm, Open-Label, Multicenter Phase II Study to Evaluate the Efficacy and Safety of HA121-28 Tablets in Patients With Medullary Thyroid Carcinoma (MTC) Recruiting NCT04787328 Phase 2 HA121-28 tablets
20 Phase II Study of Sorafenib (BAY 43-9006) in Patients With Metastatic Medullary Thyroid Carcinoma Active, not recruiting NCT00390325 Phase 2 Sorafenib Tosylate
21 Phase II Trial of Sunitinib (SU11248) in Iodine-131 Refractory, Unresectable Differentiated Thyroid Cancers and Medullary Thyroid Cancers Active, not recruiting NCT00381641 Phase 2 Sunitinib;Sunitinib Malate
22 Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults With Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors Active, not recruiting NCT02867592 Phase 2 Cabozantinib;Cabozantinib S-malate
23 A Phase I/II Study to Evaluate the Efficacy and Toxicity of Imatinib Mesylate in Combination With Dacarbazine and Capecitabine in Medullary Thyroid Carcinoma Terminated NCT00354523 Phase 1, Phase 2 Capecitabine (Xeloda);DTIC-Dome (Dacarbazine);Gleevec (Imatinib Mesylate)
24 A Targeted Ph I/II Trial of ZD6474 (Vandetanib; CAPRELSA) Plus the Proteasome Inhibitor, Bortezomib (Velcade ), in Adults With Solid Tumors With a Focus on Hereditary or Sporadic, Locally Advanced or Metastatic Medullary Thyroid Ca (MTC) Terminated NCT00923247 Phase 1, Phase 2 Bortezomib;Vandetanib
25 Adaptive Tyrosine Kinase Inhibitor Therapy In Patients With Advanced Progressive Thyroid Cancer Terminated NCT03630120 Phase 2 Lenvatinib;Sorafenib;Cabozantinib;Vandetanib
26 A Phase II Study to Evaluate the Effects of 177Lu-DOTATATE in Patients With Unresectable and Progressive Rare Metastatic Endocrine Carcinomas: Medullary Thyroid Cancer, Parathyroid Carcinoma, Pituitary Carcinoma, and Malignant Pheochromocytoma/Paraganglioma Withdrawn NCT04106843 Phase 2 Lutetium Lu 177 Dotatate
27 Randomized Double-blind Placebo Controlled Phase II Study to Evaluate the Efficacy and Safety of Sorafenib Treatment in Patients With Advanced (Recurrent, Persistent and/or Metastasizing) Medullary Thyroid Carcinoma Withdrawn NCT01736878 Phase 2 Sorafenib
28 A Phase I Trial of the mTOR Inhibitor RAD001 in Combination With VEGF Receptor Tyrosine Kinase Inhibitor PTK787/ZK 222584 in Patients With Advanced Solid Tumors Completed NCT00655655 Phase 1 everolimus;vatalanib
29 A Phase 1 Study of XL184 (Cabozantinib) in Children and Adolescents With Recurrent or Refractory Solid Tumors, Including CNS Tumors Completed NCT01709435 Phase 1 Cabozantinib S-malate
30 Phase I Study of a Recombinant Fowl Pox Vaccine rF-CEA (6D)/TRICOM Alone or With GM-CSF in Patients With Advanced CEA Expressing Adenocarinomas Completed NCT00028496 Phase 1
31 A Phase I Trial of Herceptin and Interleukin-12 Completed NCT00004074 Phase 1
32 Phase I Study of Anti-IGF-1R Monoclonal Antibody, IMC-A12, and mTOR Inhibitor, Everolimus, in Advanced Low to Intermediate Grade Neuroendocrine Carcinoma Completed NCT01204476 Phase 1 Everolimus;Octreotide Acetate
33 Phase I Clinical Trial of Temsirolimus and Vinorelbine in Advanced Solid Tumors. Completed NCT01155258 Phase 1 temsirolimus;vinorelbine ditartrate
34 Phase I Clinical Trial Using a Novel CCK-2/Gastrin Receptor-localizing Radiolabelled Peptide Probe for Personalized Diagnosis and Therapy of Patients With Progressive or Metastatic Medullary Thyroid Carcinoma Completed NCT03246659 Phase 1 111In-CP04;111In-CP04 with co-administration of gelofusine/gelaspan
35 Pilot Trial of Nivolumab Plus Cabozantinib for Advanced Solid Tumors in Patients With HIV Infection Recruiting NCT04514484 Phase 1 Cabozantinib S-malate
36 177Lu-PP-F11N for Receptor Targeted Therapy and Imaging (Theranostics) of Metastatic Medullary Thyroid Cancer - a Pilot and a Phase I Study. Recruiting NCT02088645 Phase 1 177Lu-PP-F11N
37 A Phase 1 Study of Veliparib (ABT-888) in Combination With Capecitabine and Temozolomide in Advanced Well-Differentiated Neuroendocrine Tumors Withdrawn NCT02831179 Phase 1 Capecitabine;Temozolomide;Veliparib
38 Evaluation of the Clinical Performance of 18F-FDOPA PET-CT in the Preoperative Initial Assessment of Medullary Thyroid Carcinoma: Multicenter Prospective Study Unknown status NCT03636945
39 Single Agent ZD-1839 (NSC-715055, IND-61187) in Patients With Advanced Head and Neck Carcinoma or Non-Small Cell Lung Cancer Aged 75 Years and Older (and in a Cohort of Patients 50 Years Old and Younger) Completed NCT00068497 gefitinib
40 Myeloid Cell Reprogramming in the Context of Radioiodine Therapy in Patients With Non-Medullary Thyroid Carcinoma Completed NCT03397238
41 Study of Molecular Pathways in Medullary Thyroid Carcinoma (MTC) and Correlation of Molecular Data With Clinical Behavior of the MTC in Individuals Patients Completed NCT01424878
42 Multidrug Resistance Molecular Target Analysis of Human Samples Collected in Clinical Trials Performed Outside of the Intramural National Cancer Institute Completed NCT00880503
43 177Lu-PP-F11N in Combination With Sacubitril for Receptor Targeted Therapy and Imaging of Metastatic Thyroid Cancer (Lumed Phase 0/B) Completed NCT03647657 Early Phase 1 177Lu-PP-F11N;Sacuitril
44 Utilization of the Natural History of Medullary Thyroid Carcinoma to Inform Advanced Disease Management Recruiting NCT04216732
45 Cancer Therapy Risk-Reduction With Intensive Systolic BP Management (CARISMA) - a Phase II Study Recruiting NCT04467021
46 Designing a Decision Aid to Help People With Medullary Thyroid Cancer Make Decisions With Their Doctors About Whether to Start or Stop New Drugs, Enroll in Clinical Trials, or Continue With Active Surveillance Recruiting NCT03892993
47 Longitudinal Assessment and Natural History Study of Children and Adults With MEN2A or MEN2B With or Without Medullary Thyroid Carcinoma Recruiting NCT01660984
48 Trained Immunity of Myeloid Cells and Their Progenitors in Patients With Non-medullary Thyroid Carcinoma and Colon Carcinoma Recruiting NCT05280379
49 Prospective, Single-centre, Feasibility Study to Evaluate the Use of 18F-PSMA PET/CT in Patients With Biochemically Active Medullary Thyroid Cancer Recruiting NCT05534594 18F-PSMA-1007
50 Spanish Observational Study for MOLecular Characterization of THYroid Carcinoma MOLTHY Project Recruiting NCT04970134

Search NIH Clinical Center for Thyroid Gland Medullary Carcinoma

Cochrane evidence based reviews: thyroid cancer, medullary

Genetic Tests for Thyroid Gland Medullary Carcinoma

Anatomical Context for Thyroid Gland Medullary Carcinoma

Organs/tissues related to Thyroid Gland Medullary Carcinoma:

MalaCards : Thyroid, Lymph Node, Myeloid, Pituitary, Lung, Colon, Breast

Publications for Thyroid Gland Medullary Carcinoma

Articles related to Thyroid Gland Medullary Carcinoma:

(show top 50) (show all 4443)
# Title Authors PMID Year
1
Necrosis is an independent predictor of disease-free and overall survival in pancreatic well-differentiated neuroendocrine tumours (NETs): a proposal to include it in grading systems. 62
35934531 2022
2
Rapid and long-lasting response to selpercatinib of paraneoplastic Cushing's syndrome in medullary thyroid carcinoma. 62
36069795 2022
3
Medullary Thyroid Carcinoma presenting as an Incidentaloma on Gallium-68-PSMA-PET/CT - Systematic Literature Review and Case Report. 62
35952700 2022
4
Ultrasonography screening in children and adolescents who have one parent with familial non-medullary thyroid carcinoma. 62
36124950 2022
5
Pitx2 is a useful marker of midgut-derived neuroendocrine tumours - an immunohistochemical study of 224 cases. 62
36089904 2022
6
Clinical evaluation of malignancy diagnosis of rare thyroid carcinomas by an artificial intelligent automatic diagnosis system. 62
36462146 2022
7
Temporal trends in referrals of RET gene carriers for neck surgery to a tertiary surgical center in the era of international management guidelines. 62
36456885 2022
8
Risk of malignancy in thyroid nodules with indeterminate (THY3f) cytology. 62
35446717 2022
9
Progressive metastatic pheochromocytoma induced by multiple endocrine neoplasia type 2A with a lethal outcome. 62
36341186 2022
10
[The trends in early precision diagnosis and treatment strategies of multiple endocrine neoplasia type 2]. 62
36323578 2022
11
A Retrospective Evaluation of the Diagnostic Performance of an Interdependent Pairwise MicroRNA Expression Analysis with a Mutation Panel in Indeterminate Thyroid Nodules. 62
35943886 2022
12
PET/CT in nuclear endocrinology: Results of the survey diffused through different social networks of the SEMNIM in Spain. 62
36403726 2022
13
Engineering functional 3-dimensional patient-derived endocrine organoids for broad multiplatform applications. 62
36400581 2022
14
Surgical selection and prognostic analysis in patients with unilateral sporadic medullary thyroid carcinoma. 62
35748956 2022
15
Re: Visualization of Tumor Heterogeneity in Advanced Medullary Thyroid Carcinoma by Dual-Tracer Molecular Imaging: Revealing the Theranostic Potential of SSTR- and PSMA-Directed Endoradiotherapy. 62
36215399 2022
16
Clinical practice guidelines for management of medullary thyroid carcinoma: An AGREE II appraisal. 62
36037729 2022
17
Integrated proteogenomic characterization of medullary thyroid carcinoma. 62
36344509 2022
18
Multiorgan metastases with massive bone involvement of a medullary thyroid carcinoma in a dog. 62
36444855 2022
19
Diagnostic value and cost-effectiveness of FNA-CT versus FNAC for medullary thyroid carcinoma. 62
36394172 2022
20
Distant metastasis in medullary thyroid carcinoma: Clinical outcomes and implications of T stage. 62
35261045 2022
21
Indoleamine 2,3-dioxygenase 2 immunohistochemical expression in medullary thyroid carcinoma: implications in prognosis and immunomodulatory effects. 62
36319978 2022
22
An Undetectable Postoperative Calcitonin Level Is Associated with Long-Term Disease-Free Survival in Medullary Thyroid Carcinoma: Results of a Retrospective Cohort Study. 62
36222615 2022
23
Synchronous Metastatic Medullary Thyroid Carcinoma and Paraesophageal Parathyroid Adenoma Detected on 18 F-Ethylcholine PET/US Fusion Imaging. 62
35835113 2022
24
Extensive spindling in medullary thyroid carcinoma posing a diagnostic challenge: A case report. 62
35880247 2022
25
Suboptimal accuracy of ultrasound and ultrasound-based risk stratification systems in detecting medullary thyroid carcinoma should not be overlooked. Findings from a systematic review with meta-analysis. 62
35419855 2022
26
Prognostic value of LODDS in medullary thyroid carcinoma based on competing risk model and propensity score matching analysis. 62
35821560 2022
27
The pathogenesis and treatment differences between differentiated thyroid carcinoma and medullary thyroid carcinoma. 62
35621192 2022
28
[Metastasis of medullary thyroid carcinoma to the endometrium: A case report and review of the literature]. 62
36154731 2022
29
Deep learning based on ultrasound to differentiate pathologically proven atypical and typical medullary thyroid carcinoma from follicular thyroid adenoma. 62
36201930 2022
30
Tumor Grade Predicts for Calcitonin Doubling Times and Disease-Specific Outcomes After Resection of Medullary Thyroid Carcinoma. 62
35950622 2022
31
Somatostatin receptor-directed molecular imaging for therapeutic decision-making in patients with medullary thyroid carcinoma. 62
35751778 2022
32
Reprogramming of myeloid cells and their progenitors in patients with non-medullary thyroid carcinoma. 62
36257966 2022
33
PICT-1 regulates p53 splicing and sensitivity of medullary thyroid carcinoma cells to everolimus. 62
36306198 2022
34
[MEN for multiple endocrin neoplasms: When evokate MEN? Update 2022]. 62
36307322 2022
35
Multiple endocrine neoplasia type 2 (MEN2) and RET specific modifications of the ACMG/AMP variant classification guidelines and impact on the MEN2 RET database. 62
36251279 2022
36
The effect of COVID-19 process on patients with endocrinological disease in a pandemic hospital: What happened to the others? 62
36219200 2022
37
Core Needle Biopsy in Suspicious Malignant Thyroid Nodules with Repeated Nondiagnostic Fine Needle Aspiration. 62
36452564 2022
38
MANAGEMENT OF ENDOCRINE DISEASE: Medullary thyroid cancer: from molecular biology and therapeutic pitfalls to future targeted treatment perspectives. 62
35895692 2022
39
Preclinical Evaluation of Novel Tyrosine-Kinase Inhibitors in Medullary Thyroid Cancer. 62
36139603 2022
40
A single-center multidisciplinary study analyzing thyroid nodule risk stratification by comparing the thyroid imaging reporting and data system (TI-RADS) and American thyroid association (ATA) risk of malignancy for thyroid nodules. 62
36064766 2022
41
[Clinical and genetic analysis of seven Chinese pedigrees affected with multiple endocrine neoplasia type 2A with cutaneous lichen amyloidosis]. 62
36082561 2022
42
Papillary and medullary thyroid carcinomas coexisting in the same lobe, first suspected based on fine-needle aspiration cytology: a case report. 62
36128867 2022
43
Sentinel lymph node detection in thyroid carcinoma using 68Ga-tilmanocept PET/CT: a proof-of-concept study protocol. 62
36069284 2022
44
Amphicrine Medullary Thyroid Carcinoma - a Case-Based Review Expanding on Its MUC Expression Profile. 62
35733030 2022
45
Chronology of Thyroid Cancer. 62
36153411 2022
46
Metastatic Risk Stratification of 2526 Medullary Thyroid Carcinoma Patients: A Study Based on Surveillance, Epidemiology, and End Results Database. 62
35852678 2022
47
Development and validation of an RNA sequencing-based classifier for medullary thyroid carcinoma on thyroid FNA. 62
36047747 2022
48
Management of lymph nodes in medullary thyroid carcinoma: A review. 62
36147070 2022
49
[Correlation analysis of clock genes and MEN2 medullary thyroid carcinoma]. 62
36177562 2022
50
A Rare Case of Negative Serum Calcitonin in Metastatic Medullary Thyroid Carcinoma: Diagnosis, Treatment, and Follow-Up Strategy. 62
36088532 2022

Variations for Thyroid Gland Medullary Carcinoma

Cosmic variations for Thyroid Gland Medullary Carcinoma:

8 (show top 50) (show all 298)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM88289588 VHL thyroid,NS,carcinoma,medullary carcinoma c.233A>T p.N78I 3:10142080-10142080 13
2 COSM90649998 VHL thyroid,NS,carcinoma,medullary carcinoma c.233A>T p.N78I 3:10142080-10142080 13
3 COSM122273553 TP53 thyroid,NS,carcinoma,medullary carcinoma c.241C>T p.R81* 17:7674894-7674894 13
4 COSM112255322 TP53 thyroid,NS,carcinoma,medullary carcinoma c.637C>T p.R213* 17:7674894-7674894 13
5 COSM106055208 TP53 thyroid,NS,carcinoma,medullary carcinoma c.637C>T p.R213* 17:7674894-7674894 13
6 COSM105622516 TP53 thyroid,NS,carcinoma,medullary carcinoma c.637C>T p.R213* 17:7674894-7674894 13
7 COSM121878773 TP53 thyroid,NS,carcinoma,medullary carcinoma c.241C>T p.R81* 17:7674894-7674894 13
8 COSM93185597 TP53 thyroid,NS,carcinoma,medullary carcinoma c.637C>T p.R213* 17:7674894-7674894 13
9 COSM87900604 TP53 thyroid,NS,carcinoma,medullary carcinoma c.637C>T p.R213* 17:7674894-7674894 13
10 COSM142838784 TP53 thyroid,NS,carcinoma,medullary carcinoma c.637C>T p.R213* 17:7674894-7674894 13
11 COSM143158635 TP53 thyroid,NS,carcinoma,medullary carcinoma c.160C>T p.R54* 17:7674894-7674894 13
12 COSM142562047 TP53 thyroid,NS,carcinoma,medullary carcinoma c.520C>T p.R174* 17:7674894-7674894 13
13 COSM143372968 TP53 thyroid,NS,carcinoma,medullary carcinoma c.520C>T p.R174* 17:7674894-7674894 13
14 COSM111760544 TP53 thyroid,NS,carcinoma,medullary carcinoma c.637C>T p.R213* 17:7674894-7674894 13
15 COSM143946062 TP53 thyroid,NS,carcinoma,medullary carcinoma c.160C>T p.R54* 17:7674894-7674894 13
16 COSM144311933 TP53 thyroid,NS,carcinoma,medullary carcinoma c.520C>T p.R174* 17:7674894-7674894 13
17 COSM144653365 TP53 thyroid,NS,carcinoma,medullary carcinoma c.520C>T p.R174* 17:7674894-7674894 13
18 COSM144088618 TP53 thyroid,NS,carcinoma,medullary carcinoma c.160C>T p.R54* 17:7674894-7674894 13
19 COSM144015364 TP53 thyroid,NS,carcinoma,medullary carcinoma c.604C>T p.R202* 17:7674894-7674894 13
20 COSM145020185 TP53 thyroid,NS,carcinoma,medullary carcinoma c.520C>T p.R174* 17:7674894-7674894 13
21 COSM122735989 TP53 thyroid,NS,carcinoma,medullary carcinoma c.241C>T p.R81* 17:7674894-7674894 13
22 COSM151570833 SMARCA4 thyroid,NS,carcinoma,medullary carcinoma c.2120T>C p.I707T 19:11008020-11008020 13
23 COSM140845350 SMARCA4 thyroid,NS,carcinoma,medullary carcinoma c.2120T>C p.I707T 19:11008020-11008020 13
24 COSM149469395 SMARCA4 thyroid,NS,carcinoma,medullary carcinoma c.2120T>C p.I707T 19:11008020-11008020 13
25 COSM112785467 SMARCA4 thyroid,NS,carcinoma,medullary carcinoma c.2120T>C p.I707T 19:11008020-11008020 13
26 COSM148673571 SMARCA4 thyroid,NS,carcinoma,medullary carcinoma c.2120T>C p.I707T 19:11008020-11008020 13
27 COSM151626567 SMARCA4 thyroid,NS,carcinoma,medullary carcinoma c.2120T>C p.I707T 19:11008020-11008020 13
28 COSM111398097 SMARCA4 thyroid,NS,carcinoma,medullary carcinoma c.2120T>C p.I707T 19:11008020-11008020 13
29 COSM131023754 SMARCA4 thyroid,NS,carcinoma,medullary carcinoma c.2120T>C p.I707T 19:11008020-11008020 13
30 COSM151524321 SMARCA4 thyroid,NS,carcinoma,medullary carcinoma c.2120T>C p.I707T 19:11008020-11008020 13
31 COSM89661857 SMARCA4 thyroid,NS,carcinoma,medullary carcinoma c.2120T>C p.I707T 19:11008020-11008020 13
32 COSM106821207 SMARCA4 thyroid,NS,carcinoma,medullary carcinoma c.2312T>C p.I771T 19:11008020-11008020 13
33 COSM109740002 SMARCA4 thyroid,NS,carcinoma,medullary carcinoma c.2120T>C p.I707T 19:11008020-11008020 13
34 COSM150577226 SMARCA4 thyroid,NS,carcinoma,medullary carcinoma c.2120T>C p.I707T 19:11008020-11008020 13
35 COSM151425105 SMARCA4 thyroid,NS,carcinoma,medullary carcinoma c.2120T>C p.I707T 19:11008020-11008020 13
36 COSM138940862 SMARCA4 thyroid,NS,carcinoma,medullary carcinoma c.2120T>C p.I707T 19:11008020-11008020 13
37 COSM148062262 SMARCA4 thyroid,NS,carcinoma,medullary carcinoma c.2120T>C p.I707T 19:11008020-11008020 13
38 COSM151944227 SMARCA4 thyroid,NS,carcinoma,medullary carcinoma c.2120T>C p.I707T 19:11008020-11008020 13
39 COSM151250054 SMARCA4 thyroid,NS,carcinoma,medullary carcinoma c.2120T>C p.I707T 19:11008020-11008020 13
40 COSM92347003 RET thyroid,NS,carcinoma,medullary carcinoma c.2753T>C p.M918T 10:43121968-43121968 13
41 COSM142343724 RET thyroid,NS,carcinoma,medullary carcinoma c.1289+3254T>A p.? 10:43114486-43114486 13
42 COSM142343204 RET thyroid,NS,carcinoma,medullary carcinoma c.*102T>C p.? 10:43121968-43121968 13
43 COSM90811579 RET thyroid,NS,carcinoma,medullary carcinoma c.2753T>C p.M918T 10:43121968-43121968 13
44 COSM90819239 RET thyroid,NS,carcinoma,medullary carcinoma c.1902C>G p.C634W 10:43114502-43114502 13
45 COSM92354392 RET thyroid,NS,carcinoma,medullary carcinoma c.1902C>G p.C634W 10:43114502-43114502 13
46 COSM142350315 RET thyroid,NS,carcinoma,medullary carcinoma c.*120T>C p.? 10:43121986-43121986 13
47 COSM92351620 RET thyroid,NS,carcinoma,medullary carcinoma c.1888T>C p.C630R 10:43114488-43114488 13
48 COSM142343685 RET thyroid,NS,carcinoma,medullary carcinoma c.*81G>A p.? 10:43121947-43121947 13
49 COSM142345617 RET thyroid,NS,carcinoma,medullary carcinoma c.1289+3269G>A p.? 10:43114501-43114501 13
50 COSM142349067 RET thyroid,NS,carcinoma,medullary carcinoma c.1289+3270C>G p.? 10:43114502-43114502 13

Expression for Thyroid Gland Medullary Carcinoma

Search GEO for disease gene expression data for Thyroid Gland Medullary Carcinoma.

Pathways for Thyroid Gland Medullary Carcinoma

Pathways related to Thyroid Gland Medullary Carcinoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.38 GAST CHGA CCKBR
2 10.92 MIR9-1 MIR149 MIR146B
3
Show member pathways
10.82 MIR9-1 MIR222 MIR221 MIR146B

GO Terms for Thyroid Gland Medullary Carcinoma

Cellular components related to Thyroid Gland Medullary Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 RISC complex GO:0016442 9.53 MIR9-1 MIR222 MIR221 MIR183 MIR154 MIR149
2 neuronal dense core vesicle GO:0098992 9.26 SST CHGA CALCA

Biological processes related to Thyroid Gland Medullary Carcinoma according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of cell population proliferation GO:0008285 10.11 SST NTRK1 MIR9-1 MIR221 MIR138-1 MEN1
2 positive regulation of protein kinase B signaling GO:0051897 9.88 RET MIR222 MIR221 MIR138-1
3 negative regulation of osteoblast differentiation GO:0045668 9.81 MIR9-1 MIR138-1 MEN1
4 negative regulation of inflammatory response GO:0050728 9.8 MIR222 MIR221 MIR149 MIR138-1
5 negative regulation by host of viral genome replication GO:0044828 9.52 MIR222 MIR221
6 miRNA-mediated gene silencing GO:0035195 9.47 MIR9-1 MIR222 MIR221 MIR183 MIR154 MIR149
7 negative regulation of leukocyte adhesion to vascular endothelial cell GO:1904995 9.43 MIR222 MIR221
8 negative regulation of hematopoietic stem cell proliferation GO:1902034 9.4 MIR221 MIR222
9 negative regulation of interleukin-21 production GO:0032705 9.37 MIR222 MIR221
10 negative regulation of TRAIL-activated apoptotic signaling pathway GO:1903122 9.32 MIR222 MIR221
11 positive regulation of Schwann cell migration GO:1900149 9.26 MIR222 MIR221
12 miRNA-mediated gene silencing by inhibition of translation GO:0035278 9.26 MIR9-1 MIR222 MIR221 MIR138-1
13 positive regulation of Schwann cell proliferation involved in axon regeneration GO:1905046 9.16 MIR222 MIR221

Molecular functions related to Thyroid Gland Medullary Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 hormone activity GO:0005179 9.56 TG SST GAST CALCA
2 mRNA base-pairing translational repressor activity GO:1903231 9.28 MIR9-1 MIR222 MIR221 MIR183 MIR154 MIR149

Sources for Thyroid Gland Medullary Carcinoma

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....